Absorption kinetics of L-368,899 in orally dosed female and male rats 2-a
| Dose (mg/kg) | N | AUC0–∞(μg·hr/ml) | Cmax(μg/ml) | Tmax(hr) | t½(hr) | F2-b (%) |
|---|---|---|---|---|---|---|
| 5 | ||||||
| Female | 4 | 0.38 ± 0.10 | 0.22 ± 0.13 | 0.6 ± 0.9 | 1.2 ± 0.5 | 14 |
| Male | 4 | 0.52 ± 0.14 | 0.58 ± 0.05 | 0.2 ± 0.1 | 1.0 ± 0.2 | 18 |
| 25 | ||||||
| Female | 4 | 25 ± 7 | 8.7 ± 2.6 | 0.6 ± 0.3 | 2.4 ± 0.7 | — c |
| Male | 4 | 5.5 ± 1.3 | 2.7 ± 1.1 | 0.5 ± 0 | 1.6 ± 0.7 | 41 |
| 100 | ||||||
| Female | 3 | 208 ± 14 | 26 ± 17 | 4.0 ± 2.0 | 4.1 ± 3.1 | — c |
| Male | 4 | 84 ± 36 | 17 ± 3 | 2.5 ± 1.0 | 2.3 ± 0.8 | — c |
↵2-a Mean ± SD values are listed.
↵2-b The bioavailability of the 5 mg/kg dose in male and female rats and of the 25 mg/kg dose in male rats was calculated relative to the dose adjusted-ratio AUC of the 1 and 10 mg/kg intravenous doses, respectively.
2-c Bioavailability was not calculated because plasma AUC values were outside the range observed after intravenous dosing.